NPPB and diabetes mellitus: Clinical benefits of implementing NT-proBNP screening were demonstrated by a small, randomized, single-center study, the PONTIAC (NT-proBNP Guided Primary Prevention of CV Events in DIABETIC PATIENTs) trial in which patients with diabetes in primary cardiovascular prevention with NT-proBNP > 125 pg/mL underwent therapy intensification with SRAA antagonists and/or beta-blockers, achieving a significant reduction in cardiovascular-related death and hospitalizations [55].